Edgewise Therapeutics, Inc. (EWTX) Financial Statements
Free cash flow over the same period: -$158.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
EWTXEdgewise Therapeutics, Inc.Follow EWTX — free
—
Price chart with a free account
- Market cap
- 4.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | 32.2 | 54.0 | 90.9 | 127.0 | 151.4 | 171.3 | |
| Operating income | -43.2 | -71.7 | -114.4 | -158.8 | -191.4 | -218.9 | |
| Pre-tax income | -42.8 | -67.6 | -100.2 | -133.8 | -167.8 | -197.2 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -42.8 | -67.6 | -100.2 | -133.8 | -167.8 | -197.2 | |
| Diluted EPS ($) | -1.14 | -1.26 | -1.57 | -1.45 | -1.63 | -1.86 | |
| Diluted shares (mn) | 37.5 | 53.6 | 63.7 | 92.4 | 102.9 | — |
USD millions · SEC XBRL
Edgewise Therapeutics, Inc. — questions
- What is Edgewise Therapeutics, Inc.'s net income?
- -$197.2M over the twelve months to 2026-06-30.
- What is Edgewise Therapeutics, Inc.'s free cash flow?
- -$158.8M over the twelve months to 2026-06-30.
- What are Edgewise Therapeutics, Inc.'s diluted earnings per share?
- $-1.86 over the twelve months to 2026-06-30.
Every figure on this page comes from Edgewise Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.